Key clinical point: Adding once-weekly treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide helped most patients with type 2 diabetes on sodium-glucose contransporter-2 (SGLT2) inhibitors meet glycemic targets and lose weight.
Major finding: After 30 weeks, the estimated treatment difference for hemoglobin A1c (HbA1c) favored semaglutide over placebo (–1.42; P less than .0001). Patients also lost about 3.81 kg more bodyweight with adjunctive semaglutide, compared with placebo (P less than .0001)
Study details: International, double-blind, phase 3 trial of 302 patients with type 2 diabetes with HbA1c levels of 7.0% to 10.0% despite having received at least 90 days of SGLT2-inhibitor therapy (SUSTAIN 9).
Disclosures: Novo Nordisk funded the study. Three of the authors were employees of Novo Nordisk at the time of the study, and the remaining authors reported that they and/or their institutions had received funding from the company.
Zinman B et al. Lancet Diabetes Endocrinol. 2019 Mar 1..